EIF4E and prostate carcinoma: ASOs targeting eIF4E showed efficacy in prostate cancer mouse models driven by elevated eIF4E expression; the second-generation ASO was used, retaining the phosphorothioate backbone core to initiate RNase H-mediated degradation of target mRNA and which is flanked with five 2-Methoxy methyl modified (MOE-modified) to improve strength, nuclease resistance, and tissue half-life [30].